爱泌罗(Elmiron)的用法用量:用药指南,剂量调整,特殊人群用药

Elmiron is used to treat bladder pain and discomfort caused by cystitis (inflammation or irritation of the bladder) in adults and children at least 16 years of age.

Usage and dosage of Elmiron

1. Recommended dosage

300 mg per day, that is, take one 100 mg capsule orally three times a day.

2. How to take the medicine

The capsules should be taken with water at least 1 hour before or 2 hours after a meal.

3. Medication evaluation

Patients receiving Amirol treatment should be re-evaluated after 3 months. If the condition does not improve and no limiting adverse events occur, Amirol treatment can be continued for another 3 months.

Elmiron Dose Adjustment

There are no specific dosage adjustment recommendations.

The pictures come from public channels (such as the official website of the FDA, the official website of the original drug manufacturer, etc.) and are for reference only.

Precautions for using Elmiron

1. Please follow all instructions on the prescription label, read all medication guides or instructions, and use the drug strictly according to the instructions.

2. Take Amirol with a full glass of water. It needs to be taken on an empty stomach, at least 1 hour before or 2 hours after a meal.

3. Swallow the sustained-release capsule whole. Do not crush, chew, break or open the capsule.

4. Doctors need to check the progress every 3 months to help determine the length of treatment with Almiro.

5. Blood tests and vision tests may also be needed to check for certain side effects.

6. Amuro should be stored at room temperature, away from moisture and heat sources.

Elmiron Side Effects

Get emergency medical help if you have signs of an allergic reaction: hives; trouble breathing; swelling of the face, lips, tongue, or throat.

Elmiron may cause serious side effects. Call your doctor right away if you have: nosebleeds, bleeding gums; blood in your urine or stools; rectal bleeding; coughing up blood; dizziness, feeling as if you are going to pass out; or vision problems (blurred vision, difficulty reading, difficulty seeing in low light).

Common side effects of Almiro may include: bruising, blood in the stool; hair loss; nausea, diarrhea, stomach upset; headache; swelling, weight gain; dizziness; rash; or abnormal liver function tests.

Elmiron medication for special populations

1. Pregnant women

Adequate and well-controlled clinical studies have not been conducted in pregnant women; animal reproduction studies have not shown damage to the fetus or affect fertility, but in vitro studies have shown that Elmiron at a concentration of 1 mg/mL may cause reversible limb bud abnormalities in cultured mouse embryos. Since the results of animal studies cannot fully predict human responses, they should only be used in pregnant women when clearly necessary, and doctors need to weigh the maternal and fetal benefits against potential risks.

2. Breastfeeding women

It is not yet clear whether Almera is excreted in human milk. Since most drugs can be excreted in human milk and may have potential effects on nursing infants, lactating women need to consult a doctor before using Alsurol. The doctor will comprehensively evaluate the necessity of medication and the risks to the nursing infant and decide whether to suspend breastfeeding or adjust the treatment plan.

3. Males and females with reproductive potential

It is not clear in the instructions.

4. Children

The safety and effectiveness of Amirol in children under 16 years of age have not been established, and its use is not recommended for patients in this age group.

5. Elderly people

Amirol has not yet carried out special pharmacokinetic studies in elderly patients (usually ≥65 years old). Elderly patients may have decreased physiological functions (such as liver and kidney function).

When using Almirol, it is necessary to carefully evaluate the patient's specific physical condition, comorbid diseases and medication status, and adjust the frequency of medication monitoring if necessary.

6. Renal impairment

Pharmacokinetic studies have not been conducted in patients with renal impairment. Since part of Almiro is depolymerized and metabolized in the kidneys, and some metabolites are excreted in urine, renal function impairment may affect the metabolism and excretion process of Almiro.

Therefore, patients with renal impairment should be cautious when using Almiro, and it is recommended to closely monitor renal function and possible adverse reactions.

7. Hepatic impairment

Pharmacokinetic studies have not been conducted in patients with hepatic impairment. Given the liver's involvement in the desulfation metabolism of alleron, hepatic impairment may affect the metabolism and elimination of alleron, resulting in increased drug exposure or delayed clearance.

In clinical practice, it has been observed that some patients have mild increases in liver enzymes after taking the drug. Therefore, patients with liver function impairment need to be cautious when using Almiro. It is recommended to regularly monitor liver function indicators (such as transaminases, alkaline phosphatase, etc.), and adjust medication or discontinue medication according to liver function.